Drugs / SEP 228432
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01531972 | Feb → May 2012 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEP 228432 | “Subjects will receive 40 mg of SEP 228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.” NCT01531972 ↗ |
| Route | Oral | “40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days” NCT01531972 ↗ |